Back to Dashboard
EWTX · Healthcare

EDGEWISE THERAPEUTICS INC

USA Healthcare Filing: 2025-12-31
Smart-money confidence · 1 of 3 sources firing
Bearish — money moving out

No standout activity across the feeds we track.

Hedge funds
20
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s.  ·  how the score works
◆ Next steps Interested in EDGEWISE THERAPEUTICS INC? Here's what to do with it.
Not financial advice. Bogen Capital surfaces public SEC filings — you decide what to do with them.
Market cap
$4.5B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About EDGEWISE THERAPEUTICS INC

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for…

Who's behind the signal
Every informed buyer we can see on EWTX, across all three feeds.
Hedge funds · 4
AQR Capital Management New position
Citadel Advisors Increased +452%
D.E. Shaw & Co Decreased −42%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar. EDGEWISE THERAPEUTICS INC isn't in the top-10 model right now, but 4 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
4
Investors
1
New positions
1
Increasing
2
Decreasing
0
Unchanged
Price History
Loading price data...
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
New position
% of portfolio
0.0%
Position change
NEW
0.0% of AQR Capital Management's portfolio
Trust weight: 1.0×
Increased +452%
% of portfolio
0.0%
Position change
+452%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
Decreased −42%
% of portfolio
0.0%
Position change
−42%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
Decreased −83%
% of portfolio
0.0%
Position change
−83%
0.0% of Millennium Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to EDGEWISE THERAPEUTICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell EDGEWISE THERAPEUTICS INC or any security.

Get the Weekly Update

Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime